WAT - Waters Corp Options
This article provides a detailed financial overview of Waters Corp (WAT), including its latest stock performance, key financial metrics like market cap, income, and sales, and valuation ratios. It also lists insider and institutional ownership, profitability, and various performance indicators. The data presented aims to offer a comprehensive snapshot of the company's financial health and market position.
Waters Corporation focuses on analytical instruments as investors watch long-term growth
Waters Corporation, a key player in laboratory analytical instruments, supplies solutions to pharmaceutical companies, research institutions, and industrial customers. The company's long-term growth potential is closely tied to investment cycles in drug development, quality control, and advanced materials. Its business model is anchored in life sciences, providing precision measurement systems and benefiting from recurring revenue from services and consumables.
How Investors May Respond To Thermo Fisher Scientific (TMO) Deepening Its Role In Late‑Stage mRNA Manufacturing
Thermo Fisher Scientific has deepened its involvement in late-stage mRNA manufacturing through a collaboration with Arcturus Therapeutics for the ARCT-032 cystic fibrosis therapy. This agreement strengthens Thermo Fisher's position as an end-to-end development partner in complex biologics. The company's investment narrative continues to focus on its role as a diversified provider to the pharmaceutical industry, with upcoming Q2 2026 earnings and potential impacts from China exposure and tariff pressures also being key considerations for investors.
Earnings call transcript: Becton Dickinson Q2 2026 beats earnings expectations
Becton Dickinson (BDX) exceeded Q2 2026 earnings expectations with an adjusted EPS of $2.90 on revenues of $4.7 billion, leading to a 3.9% rise in pre-market trading and increased full-year EPS guidance. The company highlighted strong growth in sectors like biologic drug delivery and advanced patient monitoring, alongside strategic initiatives for operational excellence and capital allocation, including share repurchases and maintaining a disciplined M&A approach. CEO Tom Polen and CFO Vitor Roque discussed the continued execution of the "new BD" strategy and confident outlook despite anticipated headwinds in certain markets.
How Investors Are Reacting To Qiagen (QGEN) Joining The Russell 1000 Dynamic Index
Qiagen N.V. (QGEN) has been added to the Russell 1000 Dynamic Index, increasing its visibility among institutional investors but not fundamentally changing its near-term outlook. The company recently cut its 2026 net sales growth guidance, placing more emphasis on new product launches and higher-margin platforms to offset slower growth. While some analysts have more optimistic revenue and earnings forecasts, the index inclusion primarily impacts fund trading strategies rather than immediate operational changes for Qiagen.
Waters Corporation focuses on analytical science amid steady demand
Waters Corporation (US9418481035) is a major provider of analytical instruments and laboratory solutions, with a strong presence in pharmaceuticals, life sciences, food, and environmental testing. The company's business model integrates instrument hardware, software, services, and consumables, ensuring recurring revenue and long-term customer relationships. Its strategic focus on core technologies like chromatography and mass spectrometry, coupled with ongoing innovation and a global footprint, underpins its resilience and growth in highly regulated end markets.
MTD - Mettler-Toledo International Inc Options
This article provides a detailed financial overview of Mettler-Toledo International Inc. (MTD), including its stock performance, key financial metrics, valuation ratios, and insider/institutional ownership data. It also highlights the company's EPS and sales growth, along with analyst recommendations and price targets.
Waters stock tracks its core lab testing business.
Waters Corp (WAT) specializes in analytical systems like liquid chromatography and mass spectrometry, crucial for lab testing in life sciences. The company's business model relies on instrument sales, software, consumables, and service contracts, providing a recurring revenue stream. Its stock performance directly correlates with demand in the lab testing sector, which influences order timing and margins.
WAT - Waters Corp Latest SEC Filings
This article provides the latest SEC filings and a comprehensive financial overview for Waters Corp (WAT). It details key financial metrics, stock performance data, insider transaction information, and analyst recommendations, offering a snapshot of the company's current market position and financial health.
[Form 4] WATERS CORP /DE/ Insider Trading Activity
Waters Corp director Heather Knight reported acquiring 63.03 common stock units as a compensation-related equity award, not a market trade. These units, received in lieu of director fees, were priced at $0.00 per unit and increase her direct holdings to 1,280.54 units. The units are convertible into common shares on January 1, 2027, as per a prior election.
Waters Corp (WAT) director Wei Jiang granted 67.42 deferred stock units
Waters Corp (WAT) director Wei Jiang has been granted 67.42 common stock units as compensation for director fees, bringing their total direct holdings to 3,572.75 units. These units, granted at a price of $0.00 each, are part of the company's 1996 Non-Employee Director Deferred Compensation Plan and will convert into common stock shares upon the termination of Jiang's service on the board. This transaction was reported via a Form 4 filing and is considered a neutral event for the company.
ILMN - Illumina Inc Volatility & Greeks
This article provides a detailed snapshot of Illumina Inc. (ILMN) financial and stock performance data as of July 2, 2026. It includes key metrics such as market capitalization, income, sales, various P/E ratios, EPS growth rates, insider and institutional ownership, profitability margins, and volatility indicators. The data highlights recent price changes, trading volumes, and performance over different periods.
Waters Corp explores growth opportunities as demand for analytical instruments stays resilient
Waters Corp, a global provider of analytical instruments and laboratory solutions, sees continued growth opportunities due to resilient demand for its products and services. The company benefits from its established position in high-performance liquid chromatography and mass spectrometry, serving regulated and research-intensive markets like pharmaceuticals, and generates stable recurring revenue from services and consumables. As analytical science evolves, Waters continues to innovate its technology while being influenced by spending trends in life sciences and broader market conditions.
A - Agilent Technologies Inc Latest SEC Filings
This article provides comprehensive financial data for Agilent Technologies Inc (A), including its latest stock performance, key financial metrics, valuation ratios, and institutional ownership. As of July 2nd, the stock closed at $130.69, reflecting a 2.02% decrease, with a market capitalization of $36.91 billion. The filing details various performance indicators, analyst recommendations, and upcoming earnings information.
Waters to hold Q2 2026 results call Aug. 4, webcast set
Waters Corporation (NYSE: WAT) has scheduled its second-quarter 2026 financial results conference call for Tuesday, August 4, 2026, at 8:00 a.m. Eastern Time. A live webcast and replay of the presentation will be available on the company's Investor Relations website until at least September 1, 2026. This announcement provides key financial reporting dates for investors and signals a period of updates following recent corporate activities.
Waters Corporation highlights analytical science role amid steady industry demand
Waters Corporation continues to be a crucial supplier of analytical instruments, supporting laboratories and pharmaceutical companies with precision measurement technology. The company's business model relies on instrument sales, consumables, software, and services, catering to long-term demand driven by pharmaceutical R&D, environmental monitoring, and food safety testing. Its stock offers investors exposure to the life sciences tools segment, characterized by recurring revenue and ties to regulated industries, positioning it as an infrastructure provider for scientific workflows.
GRMN - Garmin Ltd Options
This article provides a detailed financial overview of Garmin Ltd (GRMN), including its last close stock price, various financial metrics, performance indicators, and options availability. It covers aspects like market capitalization, income, sales, dividends, P/E ratios, EPS growth, insider and institutional ownership, profitability margins, and stock performance across different periods.
FIW Stock Price - First Trust Water ETF
This article provides comprehensive data on the First Trust Water ETF (FIW), including its live stock price, short-term and long-term forecasts, and key statistics like expense ratio, dividend yield, and AUM. It also lists the ETF's top holdings and performance over several years. The content aims to offer investors detailed information to evaluate FIW's investment potential.
Waters Corp. stock outperforms competitors on strong trading day
Waters Corp. (WAT) saw its stock rise by 1.67% to $375.04 on Tuesday, outperforming other major market indices. This increase occurred on a strong trading day where the S&P 500 Index and the Dow Jones Industrial Average also saw gains. The stock's positive performance ended a two-day losing streak.
Danaher Corp adjusts guidance after Masimo deal. Analysts highlight cautious upside for the stock
Danaher Corp has updated its 2026 earnings guidance to $8.35-$8.55 per share following its acquisition of Masimo Corporation, despite a 22% year-to-date share price decline. Analysts have initiated coverage with a "Neutral" rating and a $200 price target, citing fair valuation and ongoing sector headwinds. The company reported strong Q1 2026 operating metrics and order growth, suggesting a disconnect between fundamental progress and market sentiment.
Evotec launches J.TRAIN for rapid, cost-effective biologics manufacturing in partner facilities.
Evotec SE has launched J.TRAIN, a new service designed to allow biopharma companies to implement Evotec's continuous manufacturing technology within their own facilities. This solution offers a fast, flexible, and cost-effective way to produce biologics, capable of yielding over 500 kilograms of drug substance in a compact footprint and short deployment time. The innovation aims to enhance productivity and reduce costs, evidenced by a recent agreement with Sandoz.
Waters Corp. stock underperforms Monday when compared to competitors
Waters Corp. (WAT) stock fell 1.48% on Monday, closing at $368.87, despite a positive trading day for the broader market. The S&P 500 Index and Dow Jones Industrial Average both saw gains, but Waters Corp. experienced its second consecutive day of losses.
Waters Corporation with a clear analyst view, shares trade steadily on the NYSE
Waters Corporation (WAT) maintains a steady presence on the NYSE, drawing consistent analyst attention after its Q1 2026 earnings report and updated guidance. Analysts are focusing on the company's ability to achieve mid-single-digit to low-double-digit revenue growth in core markets and maintain disciplined cost control. Waters’ shares were trading around $370.00 as of June 28, 2026, supported by stable forecasts and demand for its life science instrumentation.
ACQUITY Premier System from Waters Corp - metal free flow path for tougher separations
The ACQUITY Premier System by Waters Corp is an evolution of its UHPLC platform, featuring a metal-free sample flow path to enhance separations for metal-sensitive analytes. This system addresses issues like variable peak shapes and unexplained losses in bioanalytical assays, particularly for phosphorylated peptides and metal-binding compounds. Waters positions the Premier for biopharma QC and method development groups looking to improve recovery and data robustness in demanding research and regulated environments.
Bernstein SocGen resumes Waters stock coverage with outperform rating By Investing.com
Bernstein SocGen has resumed coverage on Waters Corp. with an outperform rating and a $435 price target, noting the stock's strong first quarter 2026 report and raised guidance after previous pressures from tariff impacts and a merger announcement in 2025. Despite being considered overvalued by InvestingPro, Waters has seen renewed investor confidence, trading close to its historical median and showing significant gains in the past week. Recent company news includes new product launches for battery testing and biopharmaceutical impurity separation, along with a strategic partnership with IMU Biosciences, while Piper Sandler also initiated coverage with a Neutral rating.
Waters Corp (WAT) Financial Health: Profitability & Balance Sheet Analysis
Waters Corp (WAT) has a stable financial score of 7.65, ranking 69 out of 203 in the Healthcare Equipment & Supplies industry. The company's financial health is strong, with its latest quarterly revenue increasing by 91.48% year-over-year to $1.27 billion and net profit growing by 159.32% year-over-year. The analysis covers various financial dimensions including quality of earnings, operational efficiency, growth potential, and shareholder returns.
Merck KGaA to acquire Bio-Techne in $11.3bn deal to strengthen life sciences leadership
Merck KGaA announced its definitive agreement to acquire U.S.-based Bio-Techne Corporation for $11.3 billion (€9.9 billion) to expand its presence in high-growth life sciences markets. This acquisition, expected to close in late 2026 or early 2027, will broaden Merck's capabilities in areas like multi-omics, spatial biology, and cell and gene therapy, leveraging Bio-Techne's expertise and Merck's global reach. Merck anticipates significant financial benefits, including €140 million in annual cost synergies and positive impact on sales growth, EBITDA margin, and earnings per share.
Bruker Corp updates its scientific tools portfolio, shares tracked on NASDAQ
Bruker Corp (BRKR) is a significant player in scientific instruments and life-science tools, with its shares tracked on NASDAQ. The company draws analyst attention for its role in advanced proteomics and biopharma workflows, and its revenue is largely driven by mass spectrometry and NMR systems. Analysts focus on its earnings growth, operating margin, cash generation, and capital allocation, comparing it to peers like Thermo Fisher and Waters within the life-science tools sector.
GRAIL Secures $110 Million Investment from Samsung
GRAIL Inc. has secured a $110 million equity investment from Samsung affiliates to advance US regulatory approval and reimbursement for its Galleri multi-cancer early detection test. This funding will also support international expansion, with initial specimen testing remaining at GRAIL's North Carolina lab. As part of the agreement, GRAIL and Samsung C&T Corporation plan to collaborate on commercializing the Galleri test in South Korea, with potential expansion into other Asian markets.
SNT Biotech Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
SNT Biotech has partnered with Waters Corporation to expand access to at-home HPV cervical cancer screenings using the FDA-cleared Onclarity™ HPV Self-Collection Kit. This initiative aims to address the low screening rates among underserved populations and improve early detection, as cervical cancer is largely preventable but still claims many lives annually. The comprehensive solution combines advanced diagnostics with a patient-centric engagement platform to ensure high completion and return rates for screening kits.
SNT Biotech Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
SNT Biotech has partnered with Waters Corporation to launch a go-to-market solution for the FDA-cleared Onclarity™ HPV Self-Collection Kit, designed to expand access to at-home cervical cancer screenings across the U.S. This initiative aims to address barriers to detection, especially for underserved populations, by improving screening rates and providing a comprehensive HPV testing solution that detects 14 high-risk HPV genotypes. The platform focuses on patient engagement, education, and delivering results to help close critical care gaps and improve public health outcomes.
Waters Corporation clears a fresh analyst mark, shares trade higher on Xetra and NYSE
Waters Corporation has received renewed analyst attention, with Bernstein SocGen resuming coverage with an "outperform" rating and Piper Sandler initiating with a "neutral" rating. The company's shares are trading higher on both the NYSE and Xetra, reflecting investor interest in the life science tools sector. Analysts' price targets range between $400 and $460, with the stock currently trading within this range and showing recent gains on both exchanges.
Mettler-Toledo benefits from robust lab services outlook, shares find support in S&P 500 peer compar
Mettler-Toledo is gaining investor attention due to robust demand for laboratory equipment services and its strong competitive position within the S&P 500 healthcare tools sector. Analysts project significant growth in the global laboratory equipment services market, with Mettler-Toledo being a key participant. The company's shares, trading on the NYSE under ticker MTD, have shown resilience and positive performance compared to peers.
Bernstein SocGen resumes Waters stock coverage with outperform rating
Bernstein SocGen Group has initiated coverage on Waters Corp. (NYSE:WAT) with an "outperform" rating and a price target of $435.00, citing the company's strong replacement cycle and recent segment recovery. Despite the stock trading above InvestingPro's Fair Value estimate, making it appear overvalued in the analytical instruments sector, recent positive developments like a strong Q1 2026 report and raised guidance have supported its share price. Waters has also been active with new product launches and strategic partnerships, including a collaboration with IMU Biosciences, further enhancing its market position.
Bernstein SocGen resumes Waters stock coverage with outperform rating By Investing.com
Bernstein SocGen has resumed coverage on Waters Corp. (NYSE:WAT) with an outperform rating and a price target of $435.00, noting the stock's recent recovery and upward trend despite trading above its Fair Value estimate. The company's performance was driven by a strong replacement cycle and resilience amidst sector-wide concerns, including a significant merger announcement that initially caused a stock dip. Waters also recently launched new analytical instruments and partnered with IMU Biosciences, while Piper Sandler initiated coverage with a Neutral rating.
Is Qiagen's (QGEN) Digital PCR Expansion Quietly Redefining Its Competitive Moat in Biopharma Tools?
QIAGEN has expanded its QIAcuity digital PCR ecosystem with new gene expression assays, high-multiplex PCR kits, and enhanced automation options for biopharma users. This strategic move aims to deepen the integration of its tools and standardize high-throughput workflows, thereby strengthening Qiagen's long-term competitive position in the life sciences sector. While unlikely to immediately impact 2026 guidance, the expansion reinforces the company's innovation pipeline and supports its core investment case as a scaled diagnostics provider.
Bernstein SocGen resumes Waters stock coverage with outperform rating
Bernstein SocGen has resumed coverage on Waters Corp. (NYSE:WAT) with an outperform rating and a $435.00 price target. The firm noted Waters' strong constant currency growth in Q1 and Q2 2025, driven by a replacement cycle, despite facing sector-wide pressures and a significant stock drop after a merger announcement in July 2025. The stock has since recovered and is trending upward, with recent product launches and strategic partnerships further supporting its prospects.
Form 4 Waters Corporation For: 25 June By Investing.com
This article from Investing.com announces the filing of Form 4 for Waters Corporation on June 25. It appears to be a basic notification without further details within the provided text. The article also includes various market data and other news headlines.
Form 4 Waters Corporation For: 25 June By Investing.com
This article reports on a Form 4 filing for Waters Corporation on June 25th, indicating insider transactions. It highlights the company's stock symbol WAT and its positive performance of +2.10%. The body of the article also reiterates the filing information multiple times and mentions it was published at 05:32 p/m on June 25, 2026.
SNT Biotech Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
SNT Biotech has partnered with Waters Corporation to launch a go-to-market solution for the FDA-cleared Onclarity™ HPV Self-Collection Kit, aiming to expand access to at-home cervical cancer screenings across the U.S. This initiative addresses the high rate of preventable cervical cancer deaths by reaching unscreened or under-screened individuals through a fully integrated population health platform. The program focuses on increasing screening rates, particularly among hard-to-engage populations, by providing comprehensive patient engagement and support to ensure test completion and return.
Waters, IMU Biosciences partner to accelerate AI immune mapping for precision medicine
Waters Corporation and IMU Biosciences have announced a strategic partnership to develop an AI-powered immune mapping platform. This collaboration aims to enhance earlier disease diagnosis, continuous monitoring, and precision medicine through advanced flow cytometry and single-cell technologies combined with IMU's HD analysis and AI. The goal is to build the largest immune dataset and establish a universal standard for immune profiling to accelerate drug development for cancer and other diseases.
Illumina Jumps 7.7% Amid Sector-Wide Rally
Illumina (ILMN) saw its stock surge by 7.7% on Wednesday, closing at $177.66, driven by a broad sector-wide rally in diagnostics and research stocks. This gain was part of a larger trend, with several other life sciences companies also experiencing significant increases. The rally indicates renewed investor confidence in the life sciences tools and diagnostics sector.
10x genomics CEO Serge Saxonov sells $1.03m in stock By Investing.com
Serge Saxonov, CEO of 10x Genomics, sold 29,900 shares of company stock for over $1 million on June 22, 2026, under a pre-arranged trading plan. This sale occurred while TXG stock was trading near its 52-week high after a significant gain. The company's stock is currently considered overvalued by InvestingPro analysis, despite recent strategic moves and partnerships.
Waters Corp (WAT) Stock Up 3.4% and Still Undervalued -- GF Scor
Waters Corp (WAT) shares rose 3.4% to $369.18, and GuruFocus has assessed the stock as "modestly undervalued" with a strong GF Score of 92/100. The company shows excellent growth and valuation but has a moderate financial strength rating of 5/10, suggesting potential investors should research further despite the attractive valuation.
Waters Corp. stock underperforms Wednesday when compared to competitors despite daily gains
Waters Corp. (WAT) shares rose 3.35% on Wednesday, closing at $369.18. Despite the daily gain, the stock underperformed compared to the broader market, as the Dow Jones Industrial Average saw a gain while the S&P 500 Index experienced a slight decline. The company's stock also remains significantly below its 52-week high of $414.15.
How Revvity’s New Signals AI-Powered R&D Platform (RVTY) Has Changed Its Investment Story
Revvity, Inc. (RVTY) recently launched Signals AI within its Signals One platform, enhancing its R&D capabilities with natural language AI to transform data into scientific understanding. This move strengthens Revvity's software-led investment narrative, aiming to improve growth quality and margins through higher-margin recurring revenue streams. However, persistent regulatory and pricing pressures in China remain a key risk, and analysts hold differing views on the company's future revenue growth and profitability.
New York clears Quest Diagnostics' cancer recurrence test statewide
Quest Diagnostics (NYSE: DGX) has received New York State Department of Health CLEP approval for its Haystack MRD® ctDNA liquid biopsy test, which identifies residual or recurring disease in solid tumor cancers. This approval expands the test's availability to all 50 U.S. states. Clinical data supports the test's utility, showing it can detect complete clinical response at a median of 1.4 months, significantly faster than traditional imaging methods.
HSBC Cuts PT on Danaher Corporation (DHR) – Here’s Why
HSBC recently cut its price target on Danaher Corporation (DHR) to $230 from $270 but maintained a Buy rating, citing bearish market expectations for life science tools despite "green shoots of recovery" in bioprocessing. Separately, Wolfe Research downgraded DHR to Peer Perform, noting its valuation compared to Thermo Fisher and confusion regarding its identity after the Masimo transaction. Danaher, a significant diagnostics stock, operates across various scientific and industrial sectors.
Waters backs IMU’s AI blood test platform for cancer and other diseases
IMU Biosciences and Waters Corporation have formed a strategic partnership to advance IMU's AI-powered High Definition (HD) Immunology platform. This collaboration combines Waters Biosciences' flow cytometry and single-cell technologies with IMU's HD analysis and AI to decode the immune system at an unprecedented scale. Their goal is to transform early diagnosis, monitoring, and precision medicine for cancer and other diseases by building the world's largest immune dataset and establishing a universal standard for immune profiling.
Waters Corp (WAT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Waters Corp (WAT), detailing its price momentum score, current stock price trading range, and support/resistance levels. It also presents a comprehensive overview of various technical indicators like MACD, RSI, and moving averages, offering insights into whether the stock is a buy, sell, or neutral based on these metrics. The analysis aims to help investors understand WAT's current technical standing and potential trading signals.
